Hao Long

8PUBLICATIONS
7CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 09, 2026
Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC.

|May 16, 2026
Efficacy of Neoadjuvant Immunochemotherapy in Pulmonary Lymphoepithelioma Carcinoma Compared With Lung Squamous Cell Carcinoma and Adenocarcinoma: A Retrospective Cohort Study.

|Jun 18, 2025
Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study).

Yuheng Zhou, Zerui Zhao, Wenyu Zhai

|Sep 03, 2022
Risk stratification and prognosis prediction based on inflammation-related gene signature in lung squamous carcinoma.

Wenyu Zhai, Si Chen, Fangfang Duan

|May 09, 2022
Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy.

Zheng-Hao Ye, Hao Long, Ze-Rui Zhao

|Oct 29, 2021
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer.

Ze-Rui Zhao, Chao-Pin Yang, Si Chen

Pageof 2

Frequent Collaborators

1 joint publications

Zheng-Hao Ye

1 joint publications

Ze-Rui Zhao

1 joint publications

Fangfang Duan

1 joint publications

Junye Wang